Opinion|Videos|September 13, 2024
Video: Multisymptomatic Care in Parkinson's Disease
Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
3
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
4
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
5